References
- Alarcon T, Domingi D, Sanchez I, et al (1998). In vitro activity of ebrotidine, ranitidine, omeprazole, lansoprazole, and bismuth citrate against clinical isolates of Helicobacter pylori. Eur J Clin Microbiol & Infectious Dis, 17, 275-7.
- Hagiwara, T, Mukaisho, K, Ling, Z.-Q, et al (2007). Development of pancreatic acinar cell metaplasia after successful administration of omeprazole for 6 months in rats. Dig Dis Sci, 52, 1219-24. https://doi.org/10.1007/s10620-006-9253-7
- Hagiwara T, Mukaisho K, Nakayama T, et al (2011). Long-term proton pump inhibitor administration worsens atrophic corpus gastritis and promotes adenocarcinoma development in Mongolian gerbils infected with Helicobacter pylori. Gut, 60, 624-30 https://doi.org/10.1136/gut.2010.207662
- Larsson H, Carlsson E, Hakanson R, et al (1988). Time-course of development and reversal of gastric endocrine cell hyperplasia after inhibition of acid secretion. Studies with omeprazole and ranitidine in intact and antrectomized rats. Gastroenterology, 95, 1477-86.
- Midolo PD, Turnidge JD, Lambert JR, et al (1996). Oxygen concentration influences proton pump inhibitor activity against Helicobacter pylori in vitro. Antimicrob Agents Chemother, 40, 1531-3.
- Tatematsu M, Tsukamoto T, Mizoshita T (2005). Role of Helicobacter pylori in gastric carcinogenesis: the origin of gastric cancers and heterotopic proliferative glands in Mongolian gerbils. Helicobacter, 10, 97-106. https://doi.org/10.1111/j.1523-5378.2005.00305.x
- Tsukamoto H, Mizoshita T, Sasaki M, et al (2012). Longterm High-dose Proton Pump Inhibitor Administration to Helicobacter pylori-infected Mongolian gerbils Enhances Neuroendocrine tumor Development in the Glandular Stomach. Asian Pacific J Cancer Prev, 12, 1049-54.
Cited by
- Proton Pump Inhibitors and Helicobacter Pylori-Associated Pathogenesis vol.16, pp.4, 2015, https://doi.org/10.7314/APJCP.2015.16.4.1315